Defactinib + VS-6766 for Uveal Melanoma
Trial Summary
What is the purpose of this trial?
This trial studies the effect of combining two drugs, defactinib and VS-6766, in patients with metastatic uveal melanoma. These drugs aim to block signals in cancer cells that make them grow and spread, potentially slowing down or stopping the cancer. Everolimus has been studied in combination with other drugs for its potential to inhibit cancer cell growth in various types of tumors, including uveal melanoma.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it does mention that patients exposed to strong CYP3A4 and CYP2C9 inhibitors within 7 days prior to the first dose are excluded. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What data supports the effectiveness of the drug Defactinib + VS-6766 for Uveal Melanoma?
What makes the drug Defactinib + VS-6766 unique for uveal melanoma?
Research Team
Rino Seedor, MD
Principal Investigator
Thomas Jefferson University
Eligibility Criteria
Adults with metastatic uveal melanoma, good heart function, and no severe systemic diseases. They must not be pregnant or breastfeeding and agree to use effective contraception. Participants need stable vital signs and blood counts within specific ranges, can't have had recent major surgery or certain treatments, and must not have active infections like hepatitis or HIV.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive defactinib orally twice daily and VS-6766 twice a week for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 3 months until death or up to 2 years after the last patient is enrolled.
Treatment Details
Interventions
- Defactinib Hydrochloride
- Raf/MEK Inhibitor VS-6766
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Jefferson University
Lead Sponsor
Verastem, Inc.
Industry Sponsor